تقرير
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
| العنوان: | Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. |
|---|---|
| المؤلفون: | Li, Bob T, Meric-Bernstam, Funda, Bardia, Aditya, Naito, Yoichi, Siena, Salvatore, Aftimos, Philippe, Anderson, Ian, Curigliano, Giuseppe, de Miguel, Maria, Kalra, Maitri, Oh, Do-Youn, Park, Joon Oh, Postel-Vinay, Sophie, Rha, Sun Young, Satoh, Taroh, Spanggaard, Iben, Michelini, Flavia, Smith, Ann, Machado, Karime Kalil, Saura, Cristina |
| المصدر: | Lancet Oncol ; ISSN:1474-5488 ; Volume:25 ; Issue:6 |
| بيانات النشر: | Elsevier Science |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| الوصف: | Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate approved by the US Food and Drug Administration and the European Medicines Agency for HER2-mutant non-small-cell lung cancer. Few treatment options exist for patients with HER2-mutant solid tumours beyond lung cancers. We investigated trastuzumab deruxtecan in metastatic solid tumours with specific activating HER2 mutations. |
| نوع الوثيقة: | report article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1016/S1470-2045Test(24)00140-2; https://pubmed.ncbi.nlm.nih.gov/38710187Test |
| DOI: | 10.1016/S1470-2045(24)00140-2 |
| الإتاحة: | https://doi.org/10.1016/S1470-2045Test(24)00140-2 https://pubmed.ncbi.nlm.nih.gov/38710187Test |
| حقوق: | Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. |
| رقم الانضمام: | edsbas.8B6B4814 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/S1470-2045(24)00140-2 |
|---|